Ferric carboxymaltose: 24 month predicted versus actual analysis
Page last updated: 30 June 2017
Drug utilisation sub-committee (DUSC)
February 2017
Abstract
Purpose
To compare the predicted and actual utilisation of ferric carboxymaltose (FCM) in the first 24 months of PBS listing.
Background
FCM was listed on a cost-minimisation basis with intravenous iron polymaltose (IP) for the treatment of iron deficiency anaemia (IDA). The cost-minimisation took into account the pricing advantage for use in different treatment settings with reduced administration costs.
FCM was listed on the PBS 1 June 2014.
Data Source / methodology
The analyses used data from the Department of Human Services (DHS) supplied prescriptions database.
Key Findings
- There was a substantial growth in the total intravenous iron market after FCM was PBS-listed.
- There were 69,460 FCM prescriptions supplied in the first year of PBS listing (June 2014 to May 2015) and 125,887 prescriptions supplied in the second year (June 2015 to May 2016). In the second year, the use of FCM was higher than predicted.
- The prescriber type that wrote the largest proportion of supplied parenteral iron prescriptions was GPs.
Full Report
